NCT00833859View on ClinicalTrials.gov

Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Pancreatic Neoplasms
Interventions
DRUG

GTX (gemcitabine, docetaxel and capecitabine)

GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14

RADIATION

stereotactic body radiation therapy

stereotactic body radiation therapy (SBRT) 25

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT00833859 - Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery | Biotech Hunter | Biotech Hunter